ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below:
Conference Presentation Details:
Cowen Health Care Conference
March 8, 2023, at 9:10am ET (3:10pm CET)
Boston, MA
Full Year 2022 Release Date and Time:
March 9, 2023, 4:00 pm ET (10:00 pm CET)
Call Details:
March 10, 2023, 8:00 am ET (2:00 pm CET)
The full year 2022 results presentation will also be webcast live and will be made available on the Company’s website under the investor section. The replay will be available for 90 days following the presentation.
In order to register for the full year 2022 conference call on March 10, 2pm CET / 8am ET, please dial the following numbers approximately 10 minutes before the start of the presentation:
| Switzerland | 0800-246787 |
| USA | 1-866-652-5200 |
| Full list of dial-in numbers: | Linked here |
| Conference ID | Please ask to be joined into the Molecular Partners call. |
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
For further details, please contact:
Seth Lewis
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +1 781 420 2361
Antonio Ligi, Head of Communications
Zurich-Schlieren, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +41 79 723 36 81
| Last Trade: | US$3.58 |
| Daily Volume: | 0 |
| Market Cap: | US$131.990M |
June 22, 2025 June 11, 2025 April 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
